drugset / Trial / NCT00488839
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on spasticity. Lastly, this study will determine how long IPX056 affects spasticity.
Timeline
- Start
- 2007-06
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baclofen | Small molecule | 10 mg | — |
| Subject | Baclofen | Small molecule | 20 mg | — |
| Subject | Baclofen | Small molecule | 30 mg | — |
| Subject | Baclofen | Small molecule | 35 mg | — |
| Subject | Baclofen | Small molecule | 40 mg | — |